Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myriam Labopin

Showing results (161-170 of 443) with videos related to

Pageof 45
Sort By:
Haematologica|March 7, 2024
Incidence and outcome of central nervous system relapse after hematopoietic stem cell transplantation in patients suffering from acute myeloid leukemia and acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationSabine Blum, Yves Chalandon, Myriam Labopin, et al.
Cancer|March 29, 2016
Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationTomasz Czerw, Myriam Labopin, Norbert-Claude Gorin, et al.
American Journal of Hematology|June 13, 2020
Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantationArnon Nagler, Myriam Labopin, Jonathan Canaani, et al.
American Journal of Hematology|January 3, 2022
Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantationArnon Nagler, Myriam Labopin, Charles Craddock, et al.
Leukemia|May 16, 2020
Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemiaFrancesca Lorentino, Myriam Labopin, Fabio Ciceri, et al.
American Journal of Hematology|July 8, 2018
Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow TransplantationMaria H Gilleece, Myriam Labopin, Ibrahim Yakoub-Agha, et al.
Journal of Hematology & Oncology|January 20, 2017
Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)Xavier Poiré, Myriam Labopin, Johan Maertens, et al.
American Journal of Hematology|April 18, 2020
CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT)Enrico Maffini, Myriam Labopin, Didier Blaise, et al.
American Journal of Hematology|May 27, 2015
Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT)Xavier Poiré, Myriam Labopin, Jan J Cornelissen, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 22, 2020
Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working PartyJean El-Cheikh, Myriam Labopin, Farouk Al-Chami, et al.
Pageof 45

Showing results (161-170 of 443) with videos related to

Sort By:
Pageof 45
Haematologica|March 7, 2024
Incidence and outcome of central nervous system relapse after hematopoietic stem cell transplantation in patients suffering from acute myeloid leukemia and acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationSabine Blum, Yves Chalandon, Myriam Labopin, et al.
Cancer|March 29, 2016
Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationTomasz Czerw, Myriam Labopin, Norbert-Claude Gorin, et al.
American Journal of Hematology|June 13, 2020
Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantationArnon Nagler, Myriam Labopin, Jonathan Canaani, et al.
American Journal of Hematology|January 3, 2022
Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantationArnon Nagler, Myriam Labopin, Charles Craddock, et al.
Leukemia|May 16, 2020
Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemiaFrancesca Lorentino, Myriam Labopin, Fabio Ciceri, et al.
American Journal of Hematology|July 8, 2018
Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow TransplantationMaria H Gilleece, Myriam Labopin, Ibrahim Yakoub-Agha, et al.
Journal of Hematology & Oncology|January 20, 2017
Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)Xavier Poiré, Myriam Labopin, Johan Maertens, et al.
American Journal of Hematology|April 18, 2020
CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT)Enrico Maffini, Myriam Labopin, Didier Blaise, et al.
American Journal of Hematology|May 27, 2015
Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT)Xavier Poiré, Myriam Labopin, Jan J Cornelissen, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 22, 2020
Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working PartyJean El-Cheikh, Myriam Labopin, Farouk Al-Chami, et al.
Pageof 45